Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) target, is demonstrating promising outcomes in preliminary patient studies. Ongoing https://scrapbookmarket.com/story21353473/retatrutide-emerging-investigations-and-potential-therapeutic-applications